Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Impact of High Disease Burden on Survival in Pediatric Patients with B-ALL Treated with Tisagenlecleucel

Transplantation and Cellular Therapy(2021)10.1016/j.jtct.2021.11.019Source: DataRank Database

Impact of High Disease Burden on Survival in Pediatric Patients with B-ALL Treated with Tisagenlecleucel is a research paper published in Transplantation and Cellular Therapy (2021). On theSindex it has a DataRank of 0. It has been cited 42 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access42 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (12 grants)Impact (FWCI 2.27)OA: greenTopics (48)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (11)

Sujuan Huang,Yinmei Zhou,Patrick A. Brown ORCID,Ching‐Hon Pui ORCID,Hiroto Inaba ORCID

Live enrichment

PubMed:34875402 PMC:PMC8816862 OpenAlex:https://openalex.org/W4200075391

National Cancer Institute

Grant: P30CA021765

American Lebanese Syrian Associated Charities

Grant: CeTI2

Merck

American Society of Hematology

Kiadis Pharma

Center for Evolutionary and Theoretical Immunology

Johns Hopkins School of Medicine

Miltenyi Biotec

American Society for Transplantation and Cellular Therapy

Bristol-Myers Squibb

National Institutes of Health

St. Baldrick's Foundation

FWCI

2.27

Citation Percentile

0.9%

Citation Trend

2022

2023

2024

2025

2026

greenLicense: http://creativecommons.org/licenses/by-nc-nd/4.0/

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8816862

publisherhttps://api.elsevier.com/content/article/PII:S266663672101407X?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S266663672101407X?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.jtct.2021.11.019

Fields of Study

CAR-T cell therapy researchAcute Lymphoblastic Leukemia researchAdolescentAntigens, CD19Burkitt LymphomaChildCost of IllnessHumansPrecursor Cell Lymphoblastic Leukemia-LymphomaReceptors, Antigen, T-CellReceptors, Chimeric AntigenRecurrenceRetrospective StudiesYoung Adult

MeSH Terms

Receptors, Chimeric AntigenAdolescentBurkitt LymphomaChildHumansReceptors, Antigen, T-CellRecurrenceRetrospective StudiesCost of IllnessAntigens, CD19Precursor Cell Lymphoblastic Leukemia-LymphomaYoung Adult

Keywords

MedicineBlinatumomabCytokine release syndromeHematopoietic stem cell transplantationPopulationInternal medicineOncologyProportional hazards modelMinimal residual diseaseSurvival analysisTransplantationPediatricsImmunologyChimeric antigen receptorImmunotherapyCD19LeukemiaCancerPediatricAllCarTisagenlecleucel

Sustainable Development Goals

SDG 0: Good health and well-being